荣昌生物
(688331)
| 流通市值：45.12亿 | | | 总市值：151.65亿 |
| 流通股本：1.62亿 | | | 总股本：5.44亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,208,874,280.23 | 741,756,779.89 | 330,434,802.62 | 1,082,953,432.23 |
| 营业收入 | 1,208,874,280.23 | 741,756,779.89 | 330,434,802.62 | 1,082,953,432.23 |
| 二、营业总成本 | 2,316,244,667.13 | 1,544,261,566.81 | 682,453,542.19 | 2,632,979,340.34 |
| 营业成本 | 244,744,865.1 | 161,191,885.34 | 74,359,654.52 | 244,398,781.48 |
| 税金及附加 | 11,272,616.41 | 7,445,344.04 | 4,438,577.93 | 8,230,401.26 |
| 销售费用 | 622,700,750.52 | 389,663,250.67 | 187,504,942.42 | 775,186,042.71 |
| 管理费用 | 234,621,471.72 | 147,655,796.01 | 74,259,896 | 304,226,803.85 |
| 研发费用 | 1,153,407,440.34 | 806,232,656.31 | 331,178,800.01 | 1,306,306,793.92 |
| 财务费用 | 49,497,523.04 | 32,072,634.44 | 10,711,671.31 | -5,369,482.88 |
| 其中:利息费用 | 55,598,761.08 | 31,867,442.86 | 12,859,889.2 | 23,090,997.63 |
| 其中:利息收入 | 8,544,332.69 | 6,452,848.71 | 3,373,492.81 | 28,143,223.16 |
| 加:公允价值变动收益 | 718,287.12 | 595,107.65 | -49,464.61 | - |
| 加:投资收益 | 1,241,939 | -105,092.84 | 45,340.29 | 6,975,280.93 |
| 资产处置收益 | 88,364.48 | - | - | 4,171.21 |
| 资产减值损失(新) | -10,006,510.93 | -9,549,077.11 | - | -12,875,650.04 |
| 信用减值损失(新) | -5,774,013.88 | -3,808,126.85 | -4,658,663.1 | -11,275,815.26 |
| 其他收益 | 65,240,530.15 | 43,823,875.1 | 11,732,665.41 | 65,669,037.94 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -1,055,861,790.96 | -771,548,100.97 | -344,948,861.58 | -1,501,528,883.33 |
| 加:营业外收入 | 1,565,965.93 | 1,549,162.02 | 68,680.78 | 85,259.21 |
| 减:营业外支出 | 17,130,813.87 | 10,460,828.74 | 4,041,515.69 | 9,785,552.58 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -1,071,426,638.9 | -780,459,767.69 | -348,921,696.49 | -1,511,229,176.7 |
| 六、净利润 | -1,071,426,638.9 | -780,459,767.69 | -348,921,696.49 | -1,511,229,176.7 |
| 持续经营净利润 | -1,071,426,638.9 | -780,459,767.69 | -348,921,696.49 | -1,511,229,176.7 |
| 归属于母公司股东的净利润 | -1,071,426,638.9 | -780,459,767.69 | -348,921,696.49 | -1,511,229,176.7 |
| (一)基本每股收益 | -1.99 | -1.45 | -0.65 | -2.8 |
| (二)稀释每股收益 | -1.99 | -1.45 | -0.65 | -2.8 |
| 八、其他综合收益 | -42,366,321.69 | -25,993,401.13 | -23,282,589.1 | -58,917,976.2 |
| 归属于母公司股东的其他综合收益 | -42,366,321.69 | -25,993,401.13 | -23,282,589.1 | -58,917,976.2 |
| 九、综合收益总额 | -1,113,792,960.59 | -806,453,168.82 | -372,204,285.59 | -1,570,147,152.9 |
| 归属于母公司股东的综合收益总额 | -1,113,792,960.59 | -806,453,168.82 | -372,204,285.59 | -1,570,147,152.9 |
| 公告日期 | 2024-10-30 | 2024-08-17 | 2024-04-27 | 2024-03-28 |
| 审计意见(境内) | | | | 标准无保留意见 |